Comparison of Symptoms, Depression, Intimacy, and Quality of Life According to Treatment Duration in Men with Prostate Cancer Undergoing Androgen Deprivation Therapy

ABSTRACT

PURPOSE: This study was conducted to identify the differences in symptoms, depression, intimacy and quality of life (QOL), and the factors influencing QOL in men with prostate cancer undergoing androgen deprivation therapy (ADT). METHODS: This study used a cross-sectional, descriptive research design. Data were collected using a self-report questionnaire from 122 men with prostate cancer undergoing ADT. The data collection period was from November 19, 2018 to February 25, 2019. Data were analyzed using t-tests, χ2 tests, Fisher's exact tests, 4-way ANOVA and multiple regression. RESULTS: The mean age of the men was 70.3±7.3. There were statistically significant differences in urinary, bowel, sexual and hormonal symptoms according to treatment duration (F=23.74, p<.001). Factors influencing QOL explained 55% of the variance (adjusted R2=.55, p<.001). These factors were depression (β=−.52, p<.001), intimacy (β=.23, p=.001), ADT duration (β=−.17, p=.011), economic status middle (β=.23, p=.006), high (β=.29, p=.001) and sleep (β=.15, p=.023). CONCLUSION: The study found an association between ADT duration and symptoms, and the factors influencing QOL of participants. It provides a base for future research direction on ADT and patient QOL.